NSABP B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared with Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor—Positive Breast Cancer

Saved in:
Bibliographic Details
Published inClinical breast cancer Vol. 7; no. 5; pp. 416 - 421
Main Authors Mamounas, Eleftherios P., Lembersky, Barry, Jeong, Jong-Hyeon, Cronin, Walter, Harkins, Barbara, Geyer, Charles, Wickerham, Donald Lawrence, Paik, Soonmyung, Costantino, Joseph, Wolmark, Norman
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.12.2006
Subjects
Antineoplastic Agents, Hormonal - therapeutic use
Aromatase Inhibitors - therapeutic use
Arterial thrombotic events
Breast Neoplasms - drug therapy
Carcinoma - drug therapy
Chemotherapy, Adjuvant
Disease-Free Survival
Drug Administration Schedule
Duration of therapy
Early-stage disease
Female
Humans
Neoplasm Staging
Nitriles - therapeutic use
Osteoporotic fracture
Patient Selection
Postmenopause
Tamoxifen - therapeutic use
Triazoles - therapeutic use
Arterial thrombotic events
Duration of therapy
Osteoporotic fracture
Early-stage disease
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-News-1
ObjectType-Feature-3
content type line 23
ISSN:1526-8209
1938-0666
DOI:10.3816/CBC.2006.n.061